Piramal Pharma Limited
Piramal Pharma Limited Fundamental Analysis
Piramal Pharma Limited (PPLPHARMA.NS) shows moderate financial fundamentals with a PE ratio of -129.33, profit margin of -1.86%, and ROE of -2.03%. The company generates $88.0B in annual revenue with strong year-over-year growth of 11.78%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 34.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze PPLPHARMA.NS's fundamental strength across five key dimensions:
Efficiency Score
WeakPPLPHARMA.NS struggles to generate sufficient returns from assets.
Valuation Score
ExcellentPPLPHARMA.NS trades at attractive valuation levels.
Growth Score
ModeratePPLPHARMA.NS shows steady but slowing expansion.
Financial Health Score
ExcellentPPLPHARMA.NS maintains a strong and stable balance sheet.
Profitability Score
WeakPPLPHARMA.NS struggles to sustain strong margins.
Key Financial Metrics
Is PPLPHARMA.NS Expensive or Cheap?
P/E Ratio
PPLPHARMA.NS trades at -129.33 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, PPLPHARMA.NS's PEG of -0.67 indicates potential undervaluation.
Price to Book
The market values Piramal Pharma Limited at 2.62 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 13.47 times EBITDA. This signals the market has high growth expectations.
How Well Does PPLPHARMA.NS Make Money?
Net Profit Margin
For every $100 in sales, Piramal Pharma Limited keeps $-1.86 as profit after all expenses.
Operating Margin
Core operations generate 2.47 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-2.03 in profit for every $100 of shareholder equity.
ROA
Piramal Pharma Limited generates $-1.01 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Piramal Pharma Limited produces operating cash flow of $8.91B, showing steady but balanced cash generation.
Free Cash Flow
Piramal Pharma Limited produces free cash flow of $4.57B, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $3.46 in free cash annually.
FCF Yield
PPLPHARMA.NS converts 2.15% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-129.33
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-0.67
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.62
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.41
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.60
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.43
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.02
vs 25 benchmark
ROA
Return on assets percentage
-0.01
vs 25 benchmark
ROCE
Return on capital employed
0.02
vs 25 benchmark
How PPLPHARMA.NS Stacks Against Its Sector Peers
| Metric | PPLPHARMA.NS Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -129.33 | 29.06 | Better (Cheaper) |
| ROE | -2.03% | 646.00% | Weak |
| Net Margin | -1.86% | -44088.00% (disorted) | Weak |
| Debt/Equity | 0.60 | 0.33 | Weak (High Leverage) |
| Current Ratio | 1.43 | 4.49 | Neutral |
| ROA | -1.01% | -15444.00% (disorted) | Weak |
PPLPHARMA.NS outperforms its industry in 1 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Piramal Pharma Limited's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
183.76%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-85.52%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
2233.78%
Industry Style: Defensive, Growth, Innovation
High Growth